A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Two new RCTs of rituximab will soon begin in the United Kingdom: A biomarker-based trial with add-on belimumab and another in ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

House Republicans are considering nixing a Medicaid drug-pricing plan floated by President Trump and fiercely opposed by ...

Astrazeneca's EVP – International shares how the company is working to deliver healthcare that is inclusive, impactful and ...

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ...

AstraZeneca, a globally leading biopharmaceutical company, kicked off construction on a new small molecule drug manufacturing ...

Shares of AstraZeneca PLC (AZN) traded 1% higher in pre-market on Friday after the company reported positive results from its ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.